Q-omics provides the consensus-scored CA4 profile across patient tissues and cancer cell-line models. CA4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CA4 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, CA4 protein abundance shows 26,713 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where CA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA4 survival associations across molecular data types. CA4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA4 RNA expression–survival associations across cancer types. High CA4 expression shows unfavorable associations in ACC, SKCM and ESCA, but favorable associations in KIRC, UVM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CA4 RNA expression.
This table summarizes CA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA4 shows lower tumor expression in KIRC, COAD, LUAD, THCA, KIRP and KICH. The KIRC box plot shows higher CA4 RNA expression in normal versus tumor tissue (log2 FC = −2.300, t-test p < 0.001).
This table shows molecular features associated with CA4 in patient tissues and cancer cell lines. In patient samples, CA4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
